MiNK Therapeutics Q2 2025 Earnings Report

MiNK Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.45
• Beat/Miss: N/A
• One Year Ago EPS: N/A

MiNK Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

MiNK Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 8:30AM ET

MiNK Therapeutics (NASDAQ:INKT) (NASDAQ: INKT) is a clinical-stage biotechnology company dedicated to developing next-generation natural killer (NK) cell therapies for the treatment of cancer. The company’s proprietary MiNK platform generates memory-like NK cells with enhanced persistence, proliferative capacity and tumor-targeting activity. MiNK’s off-the-shelf, allogeneic approach is designed to overcome the manufacturing and logistical challenges associated with autologous cell therapies while maintaining potent anti-tumor efficacy.

MiNK’s product pipeline includes multiple lead candidates targeting both solid tumors and hematologic malignancies. Each candidate undergoes a standardized, closed-system manufacturing process that integrates proprietary activation, expansion and cryopreservation techniques. This process is intended to ensure consistent cell quality and facilitate rapid deployment in clinical settings. In preclinical studies, MiNK cell candidates have demonstrated tumor reduction and enhanced cytokine production in models of ovarian, lung and hematologic cancers.

The company operates research and development facilities in Massachusetts and a manufacturing site in the Midwest, with a footprint that extends to strategic collaborators in Europe and Asia. MiNK has established partnerships with leading academic medical centers and translational research institutes, enabling access to specialized expertise in immuno-oncology and streamlined pathways to early-stage clinical trials. These alliances support a global development strategy and potential future commercialization efforts.

Founded in 2017, MiNK Therapeutics is led by a seasoned executive team with deep roots in cellular therapy and drug development. The leadership group combines industry veterans and academic scientists, supported by a board of directors with experience spanning immunology, oncology and biotechnology finance. As MiNK advances its clinical pipeline, the company aims to deliver innovative, scalable immunotherapies that address unmet needs in cancer treatment.